NEW YORK (GenomeWeb) – Roche reported on Thursday a 5 percent increase in its Diagnostics division revenues for the first half of 2017, driven by strong growth in tissue diagnostics and centralized and point-of-care solutions.

For the first half ended June 30, the Swiss pharmaceuticals and diagnostics company reported sales of CHF 26.34 billion ($27.61 billion), up 5 percent from CHF 25.02 billion in the first half of 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.